CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


  • TOP

    Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.

    Mutations:

    Mutant Gene Virus Antiviral EC50 ratio Phenotype
    Y335H UL97 Human betaherpesvirus 5 Ganciclovir 0.90 No resistance
    Y335H UL97 Human betaherpesvirus 5 Maribavir 1.00 No resistance
    F342Y UL97 Human betaherpesvirus 5 Ganciclovir 5.90 High level resistance
    F342Y UL97 Human betaherpesvirus 5 Maribavir 4.20 Intermediate level resistance
    V345I UL97 Human betaherpesvirus 5 Ganciclovir 1.30 No resistance
    V345I UL97 Human betaherpesvirus 5 Maribavir 0.40 Possible hypersensitivity, no resistance
    L348V UL97 Human betaherpesvirus 5 Ganciclovir 0.90 No resistance
    L348V UL97 Human betaherpesvirus 5 Maribavir 1.60 No resistance
    E362D UL97 Human betaherpesvirus 5 Ganciclovir 3.80 Intermediate level resistance
    E362D UL97 Human betaherpesvirus 5 Maribavir 0.10 Possible hypersensitivity, no resistance
    V388M UL97 Human betaherpesvirus 5 Ganciclovir 1.20 No resistance
    V388M UL97 Human betaherpesvirus 5 Maribavir 1.10 No resistance
    H415Y UL97 Human betaherpesvirus 5 Ganciclovir 1.10 No resistance
    H415Y UL97 Human betaherpesvirus 5 Maribavir 0.60 No resistance
    A435V UL97 Human betaherpesvirus 5 Ganciclovir 1.00 No resistance
    A435V UL97 Human betaherpesvirus 5 Maribavir 0.60 No resistance
    C437Y UL97 Human betaherpesvirus 5 Ganciclovir 0.90 No resistance
    C437Y UL97 Human betaherpesvirus 5 Maribavir 0.90 No resistance


    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230